Kindred Biosciences, Inc. (KIN)
(Delayed Data from NSDQ)
$9.16 USD
+0.33 (3.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $9.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.16 USD
+0.33 (3.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $9.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Earnings Preview: Kindred Biosciences (KIN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Bio (KIN) Soars 16%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Kindred Bio (KIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kindred Bio (KIN) delivered earnings and revenue surprises of 15.15% and -0.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Kindred Biosciences (KIN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Biosciences (KIN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and 82.98%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Shares Up on Expansion of Agreement With Vaxart
by Zacks Equity Research
Kindred (KIN) expands an agreement with Vaxart for the manufacturing of the latter's oral vaccine for COVID-19 and other vaccine candidates.
Company News for Oct 8, 2020
by Zacks Equity Research
Companies in the news are: LLY, SUNW, SOL, KIN
SpringWorks Inks Deal With Pfizer for Nirogacestat Combo
by Zacks Equity Research
SpringWorks (SWTX) inks a collaboration deal with Pfizer to evaluate nirogacestat along with the latter's BCMA-targeted therapy PF-06863135 for treating relapsed/refractory multiple myeloma. Stock up.
Kala Pharmaceuticals (KALA) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Play Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
5 Stocks With Rising P/E to Snap Up for Spectacular Gains
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Encompass Health's (EHC) Expansion Plans Continue in Florida
by Zacks Equity Research
Encompass Health (EHC) continues to expand in Florida via hospitals in order to offer improved health services in the state.
Kindred Biosciences (KIN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Kindred Bio (KIN) delivered earnings and revenue surprises of 333.33% and 100.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Kindred Biosciences (KIN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Bio (KIN) Upgraded to Buy: Here's Why
by Zacks Equity Research
Kindred Bio (KIN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is the Options Market Predicting a Spike in Kindred Biosciences (KIN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Kindred Biosciences (KIN) stock based on the movements in the options market lately.
Will Kindred Biosciences (KIN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kindred Bio (KIN) delivered earnings and revenue surprises of -5.26% and -3.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Kindred Biosciences (KIN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Biosciences (KIN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kindred Bio (KIN) delivered earnings and revenue surprises of -11.43% and -28.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.